Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.
STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571.
Re
D
D
Department of Internal Medicine I, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany.
Wickenhauser
C
C
Ahmadi
T
T
Buchdunger
E
E
Kochanek
M
M
Diehl
V
V
Wolf
J
J
D001549:Benzamides; D002455:Cell Division / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D005434:Flow Cytometry; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D010879:Piperazines; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D019089:Stem Cell Factor / Q000378:metabolism; D014407:Tumor Cells, Cultured
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019089:Stem Cell Factor; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit